June 18, 2021 -- Nuevocor has completed a $24 million financing round to accelerate the preclinical development of its lead program, an adeno-associated virus (AAV)-based gene therapy for patients with cardiomyopathy due to mutations in the lamin A/C (LMNA) gene.
Nuevocor is focused on developing AAV gene therapies, and its lead program is based on research conducted by scientific cofounders Colin Stewart, PhD and Brian Burke, PhD, of Singapore's Agency for Science, Technology and Research (A*STAR).
With gene therapy experience provided by cofounder Dr. Mark Kay, PhD, from Stanford University and cardiac disease modelling expertise provided by cofounder Jianming Jiang, PhD, from the National University of Singapore, the company also plans to target other untreatable cardiomyopathies using its novel target discovery platform.
The oversubscribed series A financing round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF).
Copyright © 2021 scienceboard.net